相关实验视频

Updated: Jun 4, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

针对HR+/HER2+乳腺癌的最佳新辅助治疗策略:一个网络元分析

Shiwei Liu¹, Miao Yu¹, Exian Mou¹

¹Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

Scientific reports

|January 3, 2025

概括

对于激素受体阳性,HER2阳性乳腺癌,trastuzumab加上pertuzumab是最佳的新辅助疗法. 无人环素,含有碳酸的化疗也显示出改善病理完整反应率的希望.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
临床试验分析

背景情况:

在HER2阳性乳腺癌 (BC) 中,新辅助疗法的疗效受激素受体 (HR) 状态的影响.
尽管进行了广泛的研究,但HR+/HER2+BC的最佳新辅助剂策略仍然不清楚.

研究的目的:

为了确定HR+/HER2+乳腺癌的最佳新辅助疗法.
为了比较不同新辅助治疗策略的疗效.

主要方法:

对相关的临床试验进行系统的文献搜索.
网络元分析比较HR+/HER2+BC的新辅助疗法.
计算病理完整反应 (pCR) 的几率比率和无事件生存 (EFS) 的危险比率.

主要成果:

特拉斯图祖马布加上珀图祖马布,T-DM1和氨酸激酶抑制剂与特拉斯图祖马布疗法显示出明显更高的PCR率比单一疗法.
珀图苏马布加上特拉斯图苏马布在EFS中排名第一,而T-DM1排名最后.
没有人环素的疗法显示出略高的PCR率;含卡博普拉丁的疗法显示出数值上更高的PCR率.

结论:

特拉斯图祖马布加上珀图祖马布是HR+/HER2+BC的最佳HER2向新辅助疗法.
没有人环素的含卡博普拉丁的化疗是一种有前途的组合治疗.
需要进一步的研究来澄清内分泌治疗在HR+/HER2+BC中的作用.

关键词:

乳腺癌乳腺癌乳腺癌在HER2阳性的情况下,HER2是阳性的.人力资源积极的人力资源积极.新辅助疗法是一种新辅助疗法.网络元分析网络元分析有针对性的治疗.

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...